TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET 31
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.7 DBMR MARKET POSITION GRID 42
2.8 DBMR VENDOR SHARE ANALYSIS 43
2.9 MULTIVARIATE MODELING 44
2.10 PRODUCTS LIFELINE CURVE 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 MARKET OVERVIEW 46
3.1 DRIVERS 48
3.1.1 INCREASING USAGE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS 48
3.1.2 INCREASING GOVERNMENT INVESTMENTS, R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 49
3.2 GENETIC DISORDERS 49
3.3 RESTRAINTS 50
3.3.1 LACK OF SKILLED PROFESSIONALS 50
3.3.2 INCREASING IN-HOUSE PRODUCTION HINDERING THE GLOBAL MARKET GROWTH 51
3.4 OPPORTUNITIES 51
3.4.1 STRATEGIC INITIATIVES OF THE MARKET PLAYERS 51
3.5 DEVELOPMENTS AND INNOVATIONS OF NEW PRODUCTS 52
3.6 CHALLENGES 52
3.6.1 STRINGENT REGULATIONS 52
3.6.2 DRUG DELIVERY & TOXICOLOGY CHALLENGES 53
?
4 EXECUTIVE SUMMARY 54
4.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: SEGMENTATION 55
4.2 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026 56
5 PREMIUM INSIGHTS 57
5.1 ASIA-PACIFIC IS THE MAXIMUM GROWING AND NORTH AMERICA IS THE MOST PROFITABLE REVENUE POCKETS FOR GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE FORECAST PERIOD OF 2019 TO 2026 58
6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE 59
6.1 OVERVIEW 60
6.2 DNA OLIGONUCLEOTIDES 61
6.3 RNA OLIGONUCLEOTIDES 61
7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE 62
7.1 OVERVIEW 63
7.2 OLIGONUCLEOTIDE-BASED DRUGS 64
7.3 PRIMERS 64
7.4 PROBES 65
7.5 INTERMEDIATE-SCALE SYNTHESIZED OLIGOS 65
7.6 LARGE-SCALE SYNTHESIZED OLIGOS 66
7.7 LINKERS & ADAPTORS 66
7.8 ARRAY-BASED OLIGOS 67
8 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY CONSUMABLES 68
8.1 OVERVIEW 69
8.2 INSTRUMENTS 70
8.3 KITS & REAGENTS 70
8.4 OTHERS 71
9 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SERVICE TYPE 72
9.1 OVERVIEW 73
9.2 CUSTOM OLIGOS 74
9.2.1 MODIFICATION 74
9.2.2 PURIFICATION 74
9.3 PREDESIGNED OLIGOS 75
9.4 OLIGO SYNTHESIS 75
9.4.1 1000 NMOL 76
9.4.2 5,000 NMOL 76
9.4.3 100-200 NMOL 76
9.4.4 25-50 NMOL 76
9.4.5 10,000 NMOL 76
9.4.6 MORE THAN 10,000 NMOL 76
10 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 77
10.1 OVERVIEW 78
10.2 RESEARCH APPLICATIONS 79
10.2.1 PCR 79
10.2.2 QPCR 79
10.2.3 SEQUENCING 80
10.2.4 GENE SYNTHESIS 80
10.2.5 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 80
10.2.6 DNA MICROARRAYS 80
10.2.7 OTHER APPLICATIONS 80
10.3 THERAPEUTIC APPLICATIONS 80
10.3.1 DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES 81
10.3.2 RNAI OLIGONUCLEOTIDE-BASED THERAPIES 81
10.3.3 CPG OLIGONUCLEOTIDE-BASED THERAPIES 81
10.3.4 OTHERS 81
10.4 DIAGNOSTIC APPLICATIONS 82
10.5 OTHERS 82
11 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 83
11.1 OVERVIEW 84
11.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 85
11.3 ACADEMIC & RESEARCH INSTITUTES 85
11.4 CONTRACT RESEARCH ORGANIZATIONS 86
11.5 HOSPITALS 86
11.6 OTHERS 87
12 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY GEOGRAPHY 88
12.1 OVERVIEW 89
12.2 NORTH AMERICA 94
12.2.1 U.S. 100
12.2.2 CANADA 103
12.2.3 MEXICO 106
?
12.3 EUROPE 109
12.3.1 GERMANY 116
12.3.2 U.K. 119
12.3.3 FRANCE 122
12.3.4 SWITZERLAND 125
12.3.5 ITALY 128
12.3.6 BELGIUM 131
12.3.7 DENMARK 134
12.3.8 SWEDEN 137
12.3.9 SPAIN 140
12.3.10 NETHERLANDS 143
12.3.11 RUSSIA 146
12.3.12 TURKEY 149
12.3.13 REST OF EUROPE 152
12.4 ASIA-PACIFIC 153
12.4.1 CHINA 160
12.4.2 JAPAN 163
12.4.3 SOUTH KOREA 166
12.4.4 INDIA 169
12.4.5 AUSTRALIA 172
12.4.6 SINGAPORE 175
12.4.7 MALAYSIA 178
12.4.8 THAILAND 181
12.4.9 INDONESIA 184
12.4.10 PHILIPPINES 187
12.4.11 REST OF ASIA-PACIFIC 190
12.5 SOUTH AMERICA 191
12.5.1 BRAZIL 197
12.5.2 REST OF SOUTH AMERICA 200
12.6 MIDDLE EAST & AFRICA 201
12.6.1 SOUTH AFRICA 207
12.6.2 ISRAEL 210
12.6.3 REST OF MIDDLE EAST & AFRICA 213
13 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY LANDSCAPE 214
13.1 COMPANY SHARE ANALYSIS: GLOBAL 214
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 215
13.3 COMPANY SHARE ANALYSIS: EUROPE 216
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 217
?
14 SWOT & DBMR ANALYSIS 218
15 COMPANY PROFILE 222
15.1 DANAHER 222
15.1.1 COMPANY SNAPSHOT 222
15.1.2 REVENEUE ANALYSIS 222
15.1.3 COMPANY SHARE ANALYSIS 223
15.1.4 PRODUCT PORTFOLIO 223
15.1.5 RECENT DEVELOPMENTS 225
15.2 MERCK KGAA 226
15.2.1 COMPANY SNAPSHOT 226
15.2.2 REVENUE ANALYSIS 226
15.2.3 COMPANY SHARE ANALYSIS 227
15.2.4 SERVICE PORTFOLIO 227
15.2.5 PRODUCT PORTFOLIO 227
15.2.6 RECENT DEVELOPMENT 229
15.3 GENERAL ELECTRIC 230
15.3.1 COMPANY SNAPSHOT 230
15.3.2 REVENEUE ANALYSIS 230
15.3.3 COMPANY SHARE ANALYSIS 231
15.3.4 PRODUCT PORTFOLIO 231
15.3.5 RECENT DEVELOPMENTS 233
15.4 THERMO FISHER SCIENTIFIC INC. 234
15.4.1 COMPANY SNAPSHOT 234
15.4.2 REVENUE ANALYSIS 234
15.4.3 COMPANY SHARE ANALYSIS 235
15.4.4 SERVICE PORTFOLIO 235
15.4.5 PRODUCT PORTFOLIO 236
15.4.6 RECENT DEVELOPMENTS 237
15.5 AGILENT TECHNOLOGIES, INC. 238
15.5.1 COMPANY SNAPSHOT 238
15.5.2 REVENUE ANALYSIS 238
15.5.3 COMPANY SHARE ANALYSIS 239
15.5.4 PRODUCT PORTFOLIO 239
15.5.5 RECENT DEVELOPMENTS 240
15.6 EUROFINS SCIENTIFIC 241
15.6.1 COMPANY SNAPSHOT 241
15.6.2 REVENUE ANALYSIS 241
15.6.3 COMPANY SHARE ANALYSIS 242
15.6.4 SERVICE PORTFOLIO 242
15.6.5 RECENT DEVELOPMENTS 242
15.7 ATDBIO LTD. 243
15.7.1 COMPANY SNAPSHOT 243
15.7.2 PRODUCT PORTFOLIO 243
15.7.3 SERVICE PORTFOLIO 245
15.7.4 RECENT DEVELOPMENT 245
15.8 AJINOMOTO CO.,INC. 246
15.8.1 COMPANY SNAPSHOT 246
15.8.2 REVENUE ANALYSIS 246
15.8.3 PRODUCT PORTFOLIO 247
15.8.4 RECENT DEVELOPMENT 248
15.9 BIANOSCIENCE GMBH 249
15.9.1 COMPANY SNAPSHOT 249
15.9.2 PRODUCT PORTFOLIO 249
15.9.3 RECENT DEVELOPMENT 250
15.10 BIO BASIC INC 251
15.10.1 COMPANY SNAPSHOT 251
15.10.2 SERVICE PORTFOLIO 251
15.10.3 RECENT DEVELOPMENT 251
15.11 BIOLYTIC LAB PERFORMANCE INC. 252
15.11.1 COMPANY SNAPSHOT 252
15.11.2 PRODUCT PORTFOLIO 252
15.11.3 RECENT DEVELOPMENTS 253
15.12 BIO-SYNTHESIS INC 254
15.12.1 COMPANY SNAPSHOT 254
15.12.2 SERVICE PORTFOLIO 254
15.12.3 RECENT DEVELOPMENT 255
15.13 GENSCRIPT 256
15.13.1 COMPANY SNAPSHOT 256
15.13.2 REVENEUE ANALYSIS 256
15.13.3 PRODUCT PORTFOLIO 257
15.13.4 RECENT DEVELOPMENTS 257
15.14 KANEKA EUROGENTEC S.A. 258
15.14.1 COMPANY SNAPSHOT 258
15.14.2 PRODUCT PORTFOLIO 258
15.14.3 SERVICE PORTFOLIO 260
15.14.4 RECENT DEVELOPMENTS 260
15.15 LGC LIMITED 261
15.15.1 COMPANY SNAPSHOT 261
15.15.2 SERVICE PORTFOLIO 261
15.15.3 PRODUCT PORTFOLIO 262
15.15.4 RECENT DEVELOPMENTS 262
15.16 NITTO DENKO CORPORATION 263
15.16.1 COMPANY SNAPSHOT 263
15.16.2 REVENUE ANALYSIS 263
15.16.3 SERVICE PORTFOLIO 264
15.16.4 RECENT DEVELOPMENTS 264
15.17 POLYGEN GMBH 265
15.17.1 COMPANY SNAPSHOT 265
15.17.2 PRODUCT PORTFOLIO 265
15.17.3 RECENT DEVELOPMENT 266
15.18 QIAGEN 267
15.18.1 COMPANY SNAPSHOT 267
15.18.2 REVENUE ANALYSIS 267
15.18.3 PRODUCT PORTFOLIO 268
15.18.4 RECENT DEVELOPMENTS 268
15.19 QUINTARA BIOSCIENCES 269
15.19.1 COMPANY SNAPSHOT 269
15.19.2 PRODUCT PORTFOLIO 269
15.19.3 RECENT DEVELOPMENT 269
15.20 TRILINK BIOTECHNOLOGIES, LLC 270
15.20.1 COMPANY SNAPSHOT 270
15.20.2 PRODUCT PORTFOLIO 270
15.20.3 RECENT DEVELOPMENTS 271
15.21 TWIST BIOSCIENCE 272
15.21.1 COMPANY SNAPSHOT 272
15.21.2 REVENEUE ANALYSIS 272
15.21.3 PRODUCT PORTFOLIO 273
15.21.4 RECENT DEVELOPMENTS 273
16 CONCLUSION 274
17 QUESTIONNAIRE 275
18 RELATED REPORTS 278